In Dr, Singhal's prior study, Indocyanine Green for Intraoperative Imaging, UPCC 11510, IRB Protocol # 811870, the investigators enrolled 33 patients with lung tumors. At this time, no adverse events have occurred. Based on the extremely favorable results of this prior study, the investigators then opened the current study in order to expand the indication to patients with solid tumors including those with CNS tumors (UPCC 08913 IRB#818012). To date, 26 patients been involved in this study—8 at Pennsylvania Hospital and 18 at the Hospital of the University of Pennsylvania. All have complied and are voluntarily enrolled in our study. The data collected from the 8 patients enrolled at Pennsylvania Hospital (all with CNS tumors) have provided us with knowledge that this method of imaging can be helpful to neurosurgeons in the operating room. Because of the ability to visualize at depths below the cortical surface (using near-infrared fluorescence), the investigators have been able to better plan the incision of the dura (covering of the brain) following removal of the overlying skull. In some patients, the investigators have identified areas of brain tumor using Indocyanine Green (ICG) that would otherwise have not been resected using our traditional methods.